Compare · DXCM vs VERO
DXCM vs VERO
Side-by-side comparison of DexCom Inc. (DXCM) and Venus Concept Inc. (VERO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and VERO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 337.3x VERO ($87.7M).
- Over the past year, DXCM is down 10.6% and VERO is down 59.4% - DXCM leads by 48.8 points.
- DXCM has hit the wire 26 times in the past 4 weeks while VERO has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for VERO).
- Company
- DexCom Inc.
- Venus Concept Inc.
- Price
- $76.59+5.15%
- $1.14-6.20%
- Market cap
- $29.57B
- $87.7M
- 1M return
- +25.71%
- +0.00%
- 1Y return
- -10.56%
- -59.39%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2017
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Venus Concept Inc.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Velocity and Venus Epileve, a diode laser device for hair removal, permanent hair reduction, and treatment of ingrown hair; and Venus Fiore that is used for the treatment of vaginal canal, labia skin tightening, and mons pubis. The company also offers Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin; Venus Freeze Plus, a noninvasive device used in dermatologic and general surgical procedures for females for the noninvasive treatment of moderate to severe facial wrinkles and rhytides; Venus Bliss, a device is used for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance. In addition, it provides NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system; and ARTAS and ARTAS iX, a robotic systems to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest VERO
- Venus Concept Announces Senior Management Changes
- SEC Form D filed by Venus Concept Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Venus Concept Inc.
- Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger
- SEC Form 4 filed by Madryn Asset Management, Lp
- SEC Form 4 filed by Ew Healthcare Partners, L.P.
- SEC Form EFFECT filed by Venus Concept Inc.
- SEC Form EFFECT filed by Venus Concept Inc.
- SEC Form EFFECT filed by Venus Concept Inc.
- SEC Form EFFECT filed by Venus Concept Inc.